Effects of UHRF1 on Estrogen Receptor and Proliferation, Invasion and Migration of BCPAP Cells in Thyroid Papillary Carcinoma

XU Lin-wan, ZHANG Lu-yu, GOU Xi, QIU Yi-bo, LIU Zhi-min

Abstract

To investigate the effects of ubiquitin-like PDH and ring finger domain 1 (UHRF1) on the expression ratio of estrogen receptor (ER) α/ERβ, and to explore the experimental mechanism of UHRF1 affecting the proliferation, invasion and migration of BCPAP cells in papillary thyroid carcinoma.  Methods  The protein and mRNA expressions of UHRF1, ERα and ERβ in normal thyroid Nthy-ori3-1 cells and thyroid papillary carcinoma BCPAP cells were detected by Western blot and qRT-PCR. BCPAP cells were treated with Scrambled siRNA and UHRF1 siRNA, respectively. The expressions of ERα and ERβ mRNAs were detected by qRT-PCR. MTT and Transwell were used to determine the proliferation, invasion and migration in each group of BCPAP cells.  Results  Compared with Nthy-ori3-1 cells, the expressions of UHRF1 and ERα proteins and mRNAs in BCPAP cells were significantly up-regulated (P<0.05), while the expressions of ERβ protein and mRNA were significantly down-regulated (P<0.05). Compared with the control group and Scrambled siRNA group, the expression of ERα mRNA in BCPAP cells transfected with UHRF1 siRNA was significantly decreased (P<0.05), while the expression of ERβ mRNA was significantly increased (P<0.05). The proliferation, invasion and migration of BCPAP cells transfected with UHRF1 siRNA were significantly decreased (P<0.05).  Conclusion  UHRF1 upregulates ERα/ERβ expression ratio and promotes proliferation, invasion and migration of BCPAP cells in papillary thyroid carcinoma.

 

Keywords: UHRF1, ERα, ERβ, Papillary thyroid carcinoma

 

Full Text:

PDF


References


DALAL V， KAUR M， BANSAL A. Papillary carcinoma thyroid with anastomosing channels: an unusual morphology. J Lab Physicians，2017， 9(2): 140–142.

SIEGEL R， MA J M， ZOU Z H， et al. Cancer statistics, 2014. CA cancer J Clin，2014，64(1): 9–29.

QIU Y B， LIAO L Y， JIANG R， et al. PES1 promotes the occurrence and development of papillary thyroid cancer by upregulating the ERα/ERβ protein ratio. Sci Rep，2019，9(1): 1032[2019-12-15]. https://doi.org/ 10.1038/s41598-018-37648-7.

XUE B， ZHAO J， FENG P， et al. Epigenetic mechanism and target therapy of UHRF1 protein complex in malignancies. Onco Targets Ther， 2019，12: 549–559.

GAO S P， SUN H F， LI L D， et al. UHRF1 promotes breast cancer progression by suppressing KLF17 expression by hypermethylating its promoter. Am J Cancer Res，2017，7(7): 1554–1565.

ZHOU L， SHANG Y， JIN Z， et al. UHRF1 promotes proliferation of gastric cancer via mediating tumor suppressor gene hypermethylation. Cancer Biol Ther，2015，16(8): 1241–1251.

GE T T， YANG M， CHEN Z， et al. UHRF1 gene silencing inhibits cell proliferation and promotes cell apoptosis in human cervical squamous cell carcinoma CaSki cells. J Ovarian Res，2016，9(1): 42[2029-12-21].https://doi.org/10.1186/s13048-016-0253-8.

CHEN G G， VLANTIS A C， ZENG Q， et al. Regulation of cell growth by estrogen signaling and potential targets in thyroid cancer. Curr Cancer Drug Targets，2008，8(5): 367–377.

DAI Y J， QIU Y B， JIANG R， et al. Concomitant high expression of ERα36, GRP78 and GRP94 is associated with aggressive papillary thyroid cancer behavior. Cell Oncol，2018，41(3): 269–282.

YI J W， KIM S J， KIM J K， et al. Upregulation of the ESR1 gene and ESR ratio (ESR1/ESR2) is associated with a worse prognosis in papillary thyroid carcinoma: the impact of the estrogen receptor α/β Expression on clinical outcomes in papillary thyroid carcinoma patients. Ann Surg Oncol，2017，24(12): 3754–3762.

PARK Y R， LEE J， JUNG J H， et al. Absence of estrogen receptor is associated with worse oncologic outcome in patients who were received neoadjuvant chemotherapy for breast cancer. Asian J Surg，2020，43(3): 467–475.

BOGUSH T A， BASHARIBA A A， BOGUSH E A， et al. Estrogen receptors alpha and beta in ovarian cancer: expression level and prognosis. Dokl Biochem Biophys，2018，482(1): 249–251.

ALHOSIN M， OMRAN Z， ZAMZAMI M A， et al. Signalling pathways in UHRF1-dependent regulation of tumor suppressor genes in cancer. J Exp Clin Cancer Res，2016，35(1): 174[2019-12-15]. https://doi.org/ 10.1186/s13046-016-0453-5.

HWANG T， MATHIOS D， MCDONALD K L， et al. Integrative analysis of DNA methylation suggests down-regulation of oncogenic pathways and reduced somatic mutation rates in survival outliers of glioblastoma. Acta Neuropathol Commun，2019，7(1): 88[2019-12-16]. https://doi.org/ 10.1186/s40478-019-0744-0.

GAO L， QI X， HU K， et al. Estrogen receptor β promoter methylation: a potential indicator of malignant changes in breast cancer. Arch Med Sci， 2016，12(1): 129–136.

KIM S J， KIM T W， LEE S Y， et al. CpG methylation of the ERalpha and ERbeta genes in breast cancer. Int J Mol Med，2004，14(2): 289–293.

BARTELLA V， RIZZA P， BARONE I， et al. Erratum to: estrogen receptor beta binds Sp1 and recruits a corepressor complex to the estrogen receptor alpha gene promoter. Breast Cancer Res Treat，2016， 156(2): 409[2019-12-20]. https://doi.org/10.1007/s10549-016-3753-8.


Refbacks

  • There are currently no refbacks.